From exit to corporate growth — Houston founder talks scaling his sustainable tech

Houston innovators podcast episode 93

Robert Kester joins the Houston Innovators Podcast to discuss his entrepreneurial journey. Photo courtesy of Honeywell

There are several ways for a Houston startup to make an exit — it could IPO, receive massive private equity funding, or even get acquired. It wasn't always in the plan for Robert Kester to have his startup take the acquisition route, but he saw a huge opportunity to get the technology he had worked on for a decade into the field — and he took it.

Kester co-founded Rebellion Photonics in 2010. A doctoral candidate at Rice University at the time, Kester had an idea for scaling a sensor technology that can detect chemicals. The developed device could be used to automate the process and improve safety on oil and gas sites.

"When we first got going, it was an idea on a napkin. We had no idea if it could work or not," Kester says on this week's episode of the Houston Innovators Podcast. "So getting those first pilots from companies like BP — some of these major companies believing in us and deploying the technology. We grew it to a point where we'd shown value, and we were scaling the solution."

Kester says he initially saw this application benefitting onsite safety, but it quickly evolved into being a key took to promoting sustainability in a world where climate change is increasingly on everyone's mind. The company started considering a way to get its technology to scale — and fast. In 2019, Rebellion exited in an acquisition by Honeywell.

"For us it just made sense that we could team up with Honeywell and figure out how we could scale this thing globally and quickly, so that we could help be a solution for climate change," Kester continues.

Now, as president and general manager at Honeywell Rebellion, Kester still oversees his technology and, with the support of Honeywell, is able to see it be deployed at a quick pace.

Amid the pandemic, he was even able to make a pivot with his technology. Recognizing the importance of temperature reading as an early indicator of COVID-19, Kester and his team worked to develop ThermoRebellion, a temperature scanning technology that was implemented in airports — like JFK and Boston's Logan Airport — to screen travelers.

"I think the latest statistic I heard is that we've scanned over a million passengers coming in and out of the country," Kester says. "For me, I get a lot of satisfaction out of the fact that we're working on important issues in trying to keep the country safe."

Kester shares more about what he's focused on at Honeywell Rebellion on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

From Your Site Articles
A temperature checking technology originally created for oil and gas industry has pivoted amid the pandemic. Photo courtesy of Honeywell

Tech giant warms up to temperature monitoring system created by Houston startup

temp tech

A Houston startup's temperature monitoring system originally developed for oil and gas facilities is being used to help companies safely get their employees back into work.

The ThermoRebellion temperature software uses technology from Houston-based Rebellion Photonics, which Honeywell acquired in December of last year. The technology uses infrared imaging technology and artificial intelligence to quickly conduct non-invasive screenings of people before they enter offices, banks, airports, as businesses begin to reopen.

Robert Kester, Rebellion Photonics founder and Honeywell president and general manager, says the ongoing health crisis called for a reimagining of the AI-driven oil and gas technology, which is used to quickly detect leaks by using a real-time monitoring platform that provides automated notifications.

"The key component is our software powered by artificial intelligence," Kester tells InnovationMap. "Our imaging systems leverage a decade of experience in the most advanced imaging technologies for gas leak detection, fire detection, and intrusion monitoring applications. The system features uncooled high-resolution FPA infrared sensors allowing for each pixel to be assessed for temperature."

As states begin to lift stay-at-home orders, a return to a new normal is expected, as people begin to go back to the workplace and have to spend time in commercial buildings surrounded by others. In Houston's Memorial Hermann Hospital, temperature scanners by Austin-based Athena Security have already been installed, minimizing contact and reducing foot traffic congestion in entrances.

"Experts believe temperature checks can become more common in public spaces," says Kester. "Our system works allows for social distancing as people don't have to queue closely. Imagine an airport, for example, it wouldn't be feasible to have passengers wait in additional long lines for temperature screening."

The ThermoRebellion system can scan individuals in groups for effective screening at a wide range of sites and venues, instantly providing temperature results in an non-invasive manner, to keep employees and customers safe from introducing and spreading coronavirus.

"It's important for people to get back to work safely, whether that's an office building or a factory, or taking a flight to meet a customer," says Kester.

Honeywell is moving the technology to its piloting phase, racing against the clock to meet the demand as businesses open for business. The system, according to Kester, is intuitive and easy to use, implementing audible and visual alarms to alert if a person has elevated body temperature. Plus, it can also be easily deployed to different access points.

The fast-tracked product couldn't have been done without the team of designers and engineers who quickly pivoted from gas imaging to body temperature solutions. The team is already recruiting potential users who are interested in implementing the system in their facilities.

By Kester's and his team's estimates, the ThermoRebllion system will be ready to deploy as early as June.

"It's going to be difficult for people to go back to busy locations without knowing that companies are taking proactive steps to protect its patrons or employees," says Kester. "We're excited to be part of the set of solutions that can help improve safety."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

5 must-read innovation headlines: Pharma giant considers Houston hub + more

Trending news

Editor's note: With May coming to a close, it's time to look back at the biggest innovation headlines for the second half of the month. Major moves were made in May, with NuScale Power entering the market, Persona AI inking a deal with Under Armour, and a pharma giant considering Houston for its next manufacturing hub. Here are the most-read InnovationMap stories published May 15-29, 2026:

1. Pharma giant considers Houston for $1 billion manufacturing campus

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub. According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

2. Modular nuclear reactor co. NuScale Power moves into Houston market

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

3. Persona AI teams with Under Armour to protect next-gen robots

Houston-based Persona AI has cemented a partnership with sportswear manufacturer Under Armour to provide materials to protect future robots operating in dangerous conditions. Through the partnership, Persona AI and Under Armour will launch a research initiative to explore whether advanced performance textiles can improve the durability and resilience of humanoid robots operating in harsh industrial environments.

4. Houston quantum energy chip startup emerges from stealth with $12M round

Houston-based Casimir has emerged from stealth with a $12 million seed round to commercialize its quantum energy chip. The round was led by Austin-based Scout Ventures. Lavrock Ventures, Cottonwood Technology, Capital Factory, American Deep Tech, and Tim Draper of Draper Associates also participated in the round. The oversubscribed round exceeded the company’s original $8 million target.

5. Global summit spotlights Houston's growing role in brain health, innovation

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. The summit, held June 9-10 at the Texas Medical Center's Helix Park, will bring together more than 500 executives, researchers, policymakers and innovators from around the world to discuss the global brain economy.

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

View All Listings